Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Completed · Phase 4

Conditions studied: Multiple Sclerosis

In brief

Primary Objective: To collect blood samples in a new cohort of Relapsing Forms of Multiple Sclerosis (RMS) participants who had developed immune thrombocytopenic purpura (ITP) after LEMTRADA treatment, for future Deoxyribonucleic acid (DNA) analysis as part of a global biomarker project assessing pre-identified candidate single nucleotide polymorphisms (SNPs) associated to the development of ITP after LEMTRADA treatment in RMS participants.

Key facts

Study ID

NCT03784898

Run by

Genzyme, a Sanofi Company

People needed

13

Starts

2019-02-08

Expected to finish

2019-12-11

Last updated by the study team

2022-03-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female adult participants who had been treated with LEMTRADA, with development of ITP subsequent to treatment. Participants does not need to be currently on LEMTRADA treatment.
• Participants who had signed the study ICF.

You may not qualify if…

• Not applicable
• The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it is running

• Investigational Site Number 8400001 — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.